Clinical Trial Update: A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study tested ZEN003694 in combination with talazoparib in triple-negative breast cancer, but the trial was terminated and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Talazoparib (talazoparib)
• ZEN003694

Snippet

Sponsor: Zenith Epigenetics | Conditions: Triple Negative Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-10-07